SCHEMBL5147593

SCHEMBL5147593

CCOC(=O)CCc1cnn(C)c1NC(c1ccccc1)(c1ccccc1)c1ccccc1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP4F2 P78329 2/20 0.48
CYP4A11 Q02928 2/20 0.48
LMNA P02545 2/20 0.46
SMN1; SMN2 Q16637 4/20 0.40
TOP2A P11388 2/20 0.40
POLB P06746 1/20 0.40
MAPT P10636 1/20 0.40
CYP1A2 P05177 1/20 0.39
CYP3A4 P08684 1/20 0.39
CYP2D6 P10635 1/20 0.39
CYP2C9 P11712 1/20 0.39
CYP2C19 P33261 1/20 0.39
ALDH1A1 P00352 3/20 0.38
KDM4E B2RXH2 1/20 0.38
HSD17B10 Q99714 1/20 0.38
PPID Q08752 1/20 0.38
GAA P10253 1/20 0.37
MEN1 O00255 1/20 0.36
KMT2A Q03164 1/20 0.36
PTPN1 P18031 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5150635 0.86 HDAC6 (0.38) MAPTALDH1A1GAA
SCHEMBL17853169 0.79 ALDH1A1 (0.51) LMNASMN1; SMN2MAPTCYP3A4CYP2C19
SCHEMBL3112835 0.79 MAPK1 (0.40) LMNASMN1; SMN2ALDH1A1PPIDMEN1
SCHEMBL5148601 0.79 MTNR1B (0.39) GAA
SCHEMBL5148648 0.77 POLB (0.34) POLBKDM4EGAAMEN1KMT2A
SCHEMBL5148605 0.74 SIGMAR1 (0.43) CYP3A4GAAMEN1KMT2A
SCHEMBL5148558 0.74 MEN1 (0.33) ALDH1A1MEN1KMT2A
SCHEMBL5148585 0.73 MEN1 (0.38) ALDH1A1MEN1KMT2A
SCHEMBL17853170 0.72 KDM4C (0.42) SMN1; SMN2POLBMAPTALDH1A1KDM4E
SCHEMBL6558372 0.70 POLB (0.43) CYP4F2CYP4A11LMNASMN1; SMN2TOP2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7179801-B2 Cephem compounds ASTELLAS PHARMA INC. (JP) 2007-02-20 US disclosed
EP-1392704-B1 CEPHEM COMPOUNDS ASTELLAS PHARMA INC (JP) 2006-02-22 EP disclosed
US-20040248875-A1 Cephem compounds ASTELLAS PHARMA INC. (JP) 2004-12-09 US disclosed
EP-1392704-A1 CEPHEM COMPOUNDS FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2004-03-03 EP disclosed
WO-2002090364-A1 CEPHEM COMPOUNDS FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2002-11-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040248875-A1 Cephem compounds CEP170, C1S, SLC7A1 CYP4F2 353/4885CYP4A11 790/4885LMNA 2179/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.